Replies to post #41294 on Humanigen Inc (fka HGENQ)

[cowtown jay]

Chapter 1 The Scientific Revolution of Therapeutic Care

Humanigen's Lenzilumab is producing results that far exceed the scope of benefit beyond the application of treatment of rare blood cancer, as originally intended.

Here was the plan.

see slide 6:

https://www.humanigen.com/_files/ugd/daef6a_55106aa0f6c94de0bbb24b3e0c510201.pdf

Here is some discussion of CMML and how it can transform into Acute Myeloid Leukemia.

https://www.cancerresearchuk.org/about-cancer/other-conditions/chronic-myelomonocytic-leukaemia-cmml/what-is-cmml

We have seen both success and failure to enhance the Standard of Care drug, azacitidine. We see that Gilead's effort, using Magrolimab, failed.

https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-the-discontinuation-of-magrolimab-study-in-aml-with-tp53-mutations

However, azacitidine plus lenzilumab showed that, "... GM-CSF neutralization with LENZ and AZA resulted in changes in that trended towards normal values."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429006/

In CAR-T, lenz does more than just reduce ICANS and neurotoxicity. It also appears to improve the efficacy of the treatment therapeutic.

The degree of improvement in these cancer patients, showing normal hematological parameters, is revolutionary. It is leading to successful bone marrow transplants, as seen in the RATinG study, which could eradicate the cancer in these patients.

However, the biggest impact of lenz, which basically caused management to re-write their book, was seen in Survival Without Ventilation (SWOV) for hospitalized and hypoxic patients with covid pneumonia.

"Effect of CRP<150 mg/L on SWOV and secondary endpoints in
LIVE-AIR
In participants with baseline CRP <150 mg/L, lenzilumab
improved the likelihood of SWOV compared with placebo
(HR: 2.54; 95% CI 1.46 to 4.41; nominal p=0.0009...)"

see page 5:

https://thorax.bmj.com/content/thoraxjnl/early/2022/07/05/thoraxjnl-2022-218744.full.pdf

The NIH Covid-19 Treatment Guidelines recognized this efficacy in their March 24,2022 edition, as seen on Humanigen's home page.

"The updated interpretation of LIVE-AIR concludes “Lenzilumab improved ventilator-free survival in participants with hypoxemia who were not receiving MV, with the greatest benefit among those with lower CRP levels”, based on the increased incidence of ventilator-free survival observed in patients with CRP <150 mg/L (90% vs 79%, HR 2.54; 95% CI, 1.46–4.41; P=0.0009)."

https://www.humanigen.com/

I'm hopeful that Novavax, AstraZeneca, Janssen, and other covid vaccine manufacturers will incorporate lenz with their vaccines, and that the result will be the eradication of covid, as we may be seeing with the eradication of certain Myelodysplastic cancers.